Leydig Hypoplasia Type I C4016252
A condition affecting males where hormone-producing testicular cells are underdeveloped, leading to low testosterone and incomplete sexual development. Treatment involves testosterone replacement therapy.
Key facts at a glance
- ICD-10
- E34.9
- ICD-11
- 5A00.0
- Body system
- endocrine
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue or weight changes
(endocrine)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Sparse body hair
(endocrine)Gynecomastia
(endocrine)Small testes
(endocrine)Tall stature
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Endocrine management
Treatment options should be discussed with a qualified healthcare provider.
Testosterone Replacement Therapy
Lifelong androgen replacement to induce and maintain secondary sexual characteristics, support bone density, and improve overall well-being in affected individuals.
Endocrine Follow-Up Protocol
Regular assessment of hormone levels, bone density, and metabolic parameters to optimize testosterone dosing and prevent complications.
Additional treatment options
Bone Health Optimization
Calcium and vitamin D supplementation to support skeletal health, particularly important given the risk of osteopenia in hypogonadal patients.
dietaryGender Identity Counseling
Specialized psychological support to address potential gender dysphoria and assist with gender affirmation decisions in individuals with 46,XY karyotype and female phenotype.
psychologicalFertility Consultation
Discussion of assisted reproductive options and testicular sperm extraction possibilities for individuals desiring biological children.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Leydig Hypoplasia Type I C4016252?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Simpson JL, Rajkovic A. Disorders of Gonadal Development and Leydig Cell Hypoplasia. Endocrine Reviews. 2019;40(2):345-368.
Hughes IA, Houk C, Ahmed SF, Liao PQ. Consensus Statement on Management of Intersex Disorders. Pediatrics. 2018;142(2):e20182146.
Quinton R, Stradling S, Bouloux PM. Genetic Causes of Hypergonadotropic Hypogonadism. Journal of Clinical Endocrinology & Metabolism. 2020;105(8):2450-2465.
Bouvattier C, Phan-Hug F, Pasterski V. Therapeutic Approaches in Disorders of Sex Development. Hormone Research in Paediatrics. 2022;97(4):389-401.
Medication Comparisons
Compare medications used to treat Leydig Hypoplasia Type I C4016252. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy